Cerluten
A Khavinson lung-derived short peptide bioregulator sold in Russia as a cytomedine supplement for respiratory aging. Like the rest of the Khavinson short-peptide family, supporting evidence is almost exclusively Russian-language and of low methodological rigor by Western standards; no independent replication, no FDA or EMA status, and no controlled clinical data.
One of roughly a dozen short peptide bioregulators extracted from bovine organ tissue in the Khavinson framework (Saint Petersburg Institute of Bioregulation and Gerontology). Cerluten is the lung-tissue-derived member of the series, marketed by Peptide Bioregulators Ltd. and other Russian suppliers as an oral capsule or tablet taken in courses for respiratory aging support. As with the broader Khavinson short-peptide literature, mechanistic claims center on putative "tissue-specific" gene-expression modulation, but the supporting literature is limited to Russian-language studies from the Khavinson group and close collaborators, with minimal independent replication.
Mechanism of action
Proposed mechanism within the Khavinson bioregulator framework: short peptides cross cell membranes, enter the nucleus, and bind regulatory DNA regions in a tissue-specific fashion to modulate transcription of aging-related genes in the source tissue (here, lung). Molecular validation of this mechanism at the level of specific target genes or transcription-factor binding is minimal and has not been independently replicated outside the Khavinson group. Mechanism should be regarded as speculative.
Primary uses
- Respiratory aging support (Russian nutraceutical positioning)
- Post-pulmonary-illness recovery (Russian clinical use)
Typical dosing
The amounts in circulation come from the maker's directions, not a controlled study, so no amount is printed here.
Regulatory status
Not FDA- or EMA-approved. Sold in Russia and several CIS states as a nutraceutical cytomedine supplement, not as a registered medicine. Distributed by Peptide Bioregulators Ltd. (Saint Petersburg) and affiliated Khavinson-network suppliers.
Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
Cerluten is a Russian 'bioregulator' supplement said to contain short peptides from lung tissue, part of Vladimir Khavinson's product family. Its composition is not disclosed in a form we could check; this section records what can be checked.
Identity, computed
| Sequence | Not established |
No defined sequence is published for the product, so no formula or mass can be computed.
Regulatory status, read October 5, 2026
Drugs@FDA: 0 records for “cerluten”. EMA medicines list: 0 records for “cerluten”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from bioregulator sellers: Cerluten restores lung tissue and respiratory function with age. No controlled human study of the product was found.
About the Khavinson peptide bioregulators
The St Petersburg group's reviews, cited in References, describe short tissue-specific peptides as regulators of ageing, mostly from animal and cell work by the same group. Our Khavinson bioregulators article covers the family and the limits of that evidence.
What we looked for and did not find
No controlled human study, no defined composition, no registry record and no drug application.
| Source | Query | Results, October 5, 2026 | What it was |
|---|---|---|---|
| PubMed | cerluten | 0 | |
| PubMed | Khavinson lung peptide bioregulator | 4 | |
| ClinicalTrials.gov | cerluten | 0 | |
| Drugs@FDA (openFDA) | cerluten | 0 | |
| EMA medicines list | cerluten | 0 |
References
- [other] Khavinson VK. "Peptides and Ageing." Neuroendocrinol Lett, 2002;23 Suppl 3:1-144 (monograph covering the full Khavinson bioregulator framework).
- [review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149. PMID: 19830585.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.